MedicaidCoverageMedium impact
Molecular Biomarker Testing for Noncancer Indications - MEDICAID - VIRGINIA (New)
Humana·VA · Cardiology, Nephrology, OB-GYN +8 more·Medicaid
Effective date
Jul 1, 2025
We identified it
Jun 24, 2026
Summary
Humana has established a new Medicaid policy for molecular biomarker testing for non-cancer conditions in Virginia, effective July 1, 2025. This policy covers various genetic and biomarker tests including cardiovascular markers, kidney disease testing, prenatal screening, and gene expression profiling across multiple medical specialties.
Action Required
By July 1, 2025: Virginia Medicaid billing teams must review and implement coverage guidelines for molecular biomarker testing for non-cancer indications. Update billing systems to reflect new coverage criteria and limitations for tests including cardiovascular biomarkers (ST2), kidney disease markers (APOL1), prenatal screening panels, and gene expression profiling tests. Train staff on documentation requirements for these specialized tests.